AstraZeneca is expected to get the green light to continue its COVID-19 vaccine trial in the U.S. this week after a spinal disorder put it on hold for more than a month.
For the trial to resume, the FDA will require the biopharmaceutical company to disclose the infection that occurred on the consent form signed by trial participants, according to Reuters.
Several media outlets reported the infection to be a rare spinal disorder called transverse myelitis, an inflammation of the spinal cord that interrupts messages nerves send throughout the body.
U.K. health authorities resumed the trial after it found that there was not enough evidence to determine if the illness was caused by the vaccine.
The trial participant who was diagnosed with the disorder has been treated and discharged from a London hospital.
Pending regulatory approval, AstraZeneca plans to produce 2 billion doses of the vaccine, with 400 million to go to the U.S. and U.K.